Amarin Corp Plc (AMRN)

[retinadoc]

Data mine the Medicare or Kaiser data base.

I think we are all agreed that Amarin is no financial position to run another clinical study. The one interesting point from the Atlantic article was the mention of a possible future NIH study, which unsurprisingly the academic cardiology world favors. Draw your own conclusions as to the motivation.

A road that Amarin has not considered is to look at gross patient data since Reduce-it. Yes, this is not the gold standard RCT, but the numbers would be huge and that washes out many confounding factors. All it would take is small team of biostatisticians. Care would be needed to compare apples to apples, as I bet the patients on Vascepa are sicker, but that is certainly doable.

I despise electronic medical records, but supporters of these systems are correct that the data they contain is pure gold.